文献速递中医内科中药与中成药合理使用针灸推拿

靶向肠道菌群治疗2型糖尿病:中医药的干预潜力

Management of Type 2 Diabetes Mellitus: Targeting Gut Microbiome Therapy.
PubMed 文献 · Am J Chin Med · 2026-07-06

本文综述了2型糖尿病(T2DM)与肠道菌群的关联,重点探讨中药提取物(如黄芩苷、小檗碱、四氢姜黄素、人参皂苷Rb1、麦冬皂苷D、白藜芦醇)、复方及针灸通过调节肠道菌群生态系统管理T2DM的潜力。现有证据多来自动物模型和早期临床试验,缺乏足够临床证据确认疗效,未来需大规模临床试验和多组学研究。

要点

  • 肠道菌群组成与代谢活动与T2DM发生发展密切相关。
  • 黄芩苷、小檗碱等中药提取物及针灸可能通过调节肠道菌群延缓T2DM进展。
  • 现有证据多限于动物模型和早期临床试验,临床验证不足。

核心结论

  • 中医药干预可能通过调节肠道菌群生态系统延缓T2DM进展,但现有临床证据不足。

研究设计与样本

  • 综述,检索范围未明确报告。

主要发现

  • 肠道菌群组成和代谢活动与T2DM发生发展密切相关。
  • 黄芩苷、小檗碱、四氢姜黄素、人参皂苷Rb1、麦冬皂苷D、白藜芦醇、复方及针灸具有调节肠道菌群治疗T2DM的潜力。
  • 多数研究局限于动物模型和早期临床试验,缺乏足够临床证据确认疗效。

临床怎么用

  • 临床可关注中医药调节肠道菌群治疗T2DM的潜力,但需向患者说明现有证据多来自动物和早期试验。

局限性

  • 多数研究为动物模型和早期临床试验,缺乏足够临床证据确认疗效。
  • 理论应用与临床验证之间存在不平衡。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Marked by high blood glucose and systemic metabolic dysfunction, type 2 diabetes mellitus (T2DM) is a significant health issue with a rapidly increasing worldwide prevalence. Recent studies have highlighted the gut microbiota as a key determinant of host metabolism, and identified that the composition and metabolic activity are closely linked to the development and progression of T2DM. This review comprehensively explores the intricate connection between T2DM and the gut microbiota, with a particular focus on how traditional Chinese medicine (TCM) can influence intestinal microbiota composition to manage disease. It also discusses the therapeutic potential of TCM, which includes natural medicinal extracts like baicalin, berberine, tetrahydrocurcumin, ginsenoside Rb1, ophiopogonin D, and resveratrol, compound formulations, and acupuncture, in regulating the intestinal microbiota ecosystem to manage T2DM. Although the current evidence suggests that these interventions may slow T2DM progression, most studies have been confined to animal models and early clinical trials which lack adequate clinical evidence to confirm their efficacy. This discrepancy has created an imbalance between theoretical and validated clinical applications. Building on existing research, future research should focus on large-scale clinical trials and advanced multi-omics studies to uncover the potential of TCM in managing T2DM through the gut microbiota.

来源:Am J Chin Med,查看原文。版权归原作者所有。

引用

  1. Bibi A, Zhou L, You M, et al. Management of Type 2 Diabetes Mellitus: Targeting Gut Microbiome Therapy. Am J Chin Med. 2026. PMID: 42417102. doi:10.1142/S0192415X26500497

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。